Grove Front Entrance
Dr Laith Alrubaiy

Dr Laith Alrubaiy

Honorary Chair, Medicine Health and Life Science

Telephone number

+44 (0) 1792 602435

Email address

Available For Postgraduate Supervision


Professor Laith Alrubaiy is a consultant Gastroenterologist and Hepatologist. He is an Honorary Professor at Swansea University Medical School. After winning two highly competitive scholarships to complete his post graduate medical studies at the State University of New York in the USA and then at King’s College London in the UK, he moved to Wales to pursue his clinical academic trainings in Wales in Hepatology, Gastroenterology and General Medicine. He was awarded a PhD from Swansea University School of Medicine for his work in applying health informatics in Gastroenterology research and clinical trials. He is an expert in patients’ reported outcome measures (PROMs) related research. He has won several national and international awards. In 2017, he was named the “Young Gastroenterologist of the Year” by the British Society of Gastroenterology in the UK.

In addition to his academic work at Swansea University Medical School, Dr Alrubaiy continues his clinical work as an Honorary Consultant Gastroenterologist and Hepatologist at St Mark’s Hospital in London, one of the biggest GI specialised hospitals in Europe.      

Areas Of Expertise

  • Gastroenterology and Hepatology
  • Patient Reported Outcome Measures ( PROMS)
  • Clinical Trials
  • Global Health
  • Medicine in Low Income Countries

Career Highlights

Award Highlights


  • Staff Excellence Award nominee: Quality and Improvement. London North West NHS University Healthcare Trust 2022
  • St David’s Award finalist: Welsh Government 2019
  • Staff Recognition award from going the extra mile to help patients. University Hospital of Wales 2018.
  • Young Gastroenterologists of the year 2017 – Emerging Leader award- by the British Society of Gastroenterology
  • Finalist for the NHS Wales Awards 2014 “Developing new outcome measures to assess the quality of life and disease severity in patients with inflammatory bowel disease”